Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
20.-22.01.2022 online: ANIM: NeuroIntensivmediziner diskutieren neue Erkenntnisse zu COVID-19
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
Weight-loss surgery increases alcohol use disorders over time
NIH-funded study sheds light on risk of bariatric procedures
Bethesda, MD, USA (June 18, 2012) – Adults who had a common bariatric surgery to lose weight had a significantly higher risk of alcohol use disorders (AUD) two years after surgery, according to a study by a National Institutes of Health research consortium.
Researchers investigated alcohol consumption and alcohol use disorders symptoms in 1,945 participants from the NIH-funded Longitudinal Assessment of Bariatric Surgery (LABS), a prospective study of patients undergoing weight-loss surgery at one of 10 hospitals across the United States. Within 30 days before surgery, and again one and two years after surgery, study participants completed the Alcohol Use Disorders Identification (AUDIT) test. The test, developed by the World Health Organization, identifies symptoms of alcohol use disorders, a condition that includes alcohol abuse and dependence, commonly known as alcoholism.
Study participants were categorized as having AUD if they had at least one symptom of alcohol dependence, which included not being able to stop drinking once started, or alcohol-related harm, which included not being able to remember, or if their total AUDIT score was at least 8 (out of 40).
About 70 percent of the study participants had Roux-en-Y (RYGB) gastric bypass surgery, which reduces the size of the stomach and shortens the intestine, limiting food intake and the body’s ability to absorb calories. Another 25 percent had laparoscopic adjustable gastric banding surgery, which makes the stomach smaller with an adjustable band. About 5 percent of the patients had other, less common weight-loss surgeries.
Among participants who had the RYGB procedure, 7 percent reported symptoms of alcohol use disorders prior to surgery. There was no significant increase in AUD one year after surgery. However, by the second year after surgery, 10.7 percent of patients reported symptoms of AUD, a relative increase of more than 50 percent compared to pre-surgical rates.
One in 8 LABS study participants reported having at least three drinks on a typical drinking day the second year after surgery. “This is concerning, given the negative impact heavy drinking may have on vitamin and mineral status, liver function and weight loss,” said Dr. Wendy King, the study’s lead author and an assistant professor in the Department of Epidemiology at the University of Pittsburgh Graduate School of Public Health.
Although AUD prior to surgery was one of the strongest predictors of AUD after surgery, more than half of study participants with AUD after surgery did not report having the condition during the year before surgery.
Regular alcohol use before surgery—at least two drinks per week—was also independently related to a higher risk of postoperative AUD. In addition to prior AUD and drinking frequency, patients with less social support or who reported preoperative recreational drug use or smoking before surgery were more likely to report symptoms of AUD after surgery. Men and younger adults were also more likely to develop AUD. Depressive symptoms, mental health treatment, and binge eating prior to surgery were not independently related to an increased likelihood of AUD after surgery.
“The study results suggest that clinicians should be aware of the importance of monitoring for signs and symptoms of AUD and consider counseling after bariatric surgery” said Dr. Mary Horlick, project scientist for LABS at the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Previous studies suggesting that bariatric surgery may increase the risk for alcohol use disorders were small, retrospective and used a variety of assessment methods. “This first prospective study of AUD symptoms before and after surgery was done in a large number of people from 10 hospitals across the United States, using a validated and reliable alcohol use screening method,” said Horlick.
Study results will be posted on the Journal of the American Medical Association’s website on June 18 and presented at the American Society for Metabolic and Bariatric Surgery meeting in San Diego the same day. The study also will appear in JAMA’s June 20, 2012, print issue.
The prevalence of bariatric surgery to treat obesity has increased dramatically with the use of less-invasive laparoscopic techniques and availability of additional surgical procedures. More than one-third of U.S. adults are obese (having a body mass index, or BMI, of 30 or higher), and almost 6 percent are extremely obese, defined as a BMI of 40 or more. BMI is a measure of weight in relation to height.
Initially, bariatric surgery was reserved for people with a BMI of 40 or higher, or a BMI of 35 or higher with a serious health problem. Mounting evidence that supports the surgery’s effectiveness in helping people shed pounds, reverse risk factors for heart disease, and in some cases, reverse type 2 diabetes, has led doctors to consider it as a therapy for people with less severe obesity.
"These findings show that there is much more to learn about bariatric surgery and how it influences a patient’s health and well-being” said NIDDK Director Dr. Griffin P. Rodgers. “It is important that patients and their doctors be fully aware of short- and long-term benefits and risks of bariatric surgery. We hope the LABS results will help researchers identify clinical questions that require further research, including better understanding of the risk of AUD.”
Find more information about LABS (NCT00465829) at www.niddklabs.org. The research is funded by NIDDK grants U01DK066557, U01DK066667, U01DK066568, U01DK066471, U01DK066526, U01DK066585 and U01DK066555. Additional support was provided by NIH’s National Center for Research Resources, now the National Center for Advancing Translational Sciences, under grants M01RR00037, UL1RR024996, and UL1RR024153.
The NIDDK, part of the NIH, conducts and supports basic and clinical research and research training on some of the most common, severe and disabling conditions affecting Americans. The Institute’s research interests include: diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic and hematologic diseases. For more information, visit www.niddk.nih.gov
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov
National Institutes of Health (NIH), 18.06.2012 (tB).